- Investing Ideas
- /
- Australian Biotech Breakthroughs
Australian Biotech Breakthroughs
Results
5
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
5 companies
Mesoblast
Market Cap: AU$3.5b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.71
7D
17.3%
1Y
53.1%
Immutep
Market Cap: AU$448.9m
A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.30
7D
17.3%
1Y
-6.2%
PYC Therapeutics
Market Cap: AU$933.2m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.60
7D
15.9%
1Y
-13.5%
Aroa Biosurgery
Market Cap: AU$227.7m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.66
7D
-1.5%
1Y
-6.4%
Paradigm Biopharmaceuticals
Market Cap: AU$165.0m
Engages in the research and development of therapeutic products for human use in Australia.
PAR
AU$0.39
7D
26.2%
1Y
-25.2%